siRNAsense AS is a biotechnology company developing new drugs focused on cancer and neuroscience, based on RNA interference, RNAi. RNA interference is a newly discovered natural process within the cells, and has a potential of bringing new and more effective drugs to the market based on completely new mechanisms of action. Our scientific staff are among the early adopters of this technology, and siRNAsense is developing a pipeline of drugs based on this broad knowledge and competence.

 

Ownership structure - largest shareholders:

Dag Dvergsten AS
 

Management and board: Click here

 

Investor relations:
Phone:     +47 22 94 77 00
E-mail:     sirnasense[at]sirnasense.com

 >90 %